Simulations Plus (SLP) Highlights FDA Alignment as Citizens Maintains Market Perform [Yahoo! Finance]
Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development [Yahoo! Finance]
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
Simulations Plus (NASDAQ:SLP) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.